The Cancer Immunotherapy Market is being driven by High prevalence of cancer
The Cancer Immunotherapy Market is expected to grow at a CAGR of 8.1% during 2023 and 2028. During this period, the market is also expected to show a growth of USD 45.5 billion. In the dynamic and competitive landscape of the cancer immunotherapy market, vendors are employing strategic initiatives to expand their presence and enhance their competitive edge. These strategies include the acquisition or licensing of promising drug candidates and technologies from smaller biotech firms and academic institutions, bolstering pipelines and fortifying market positions. Mergers and acquisitions serve as crucial tools for gaining access to complementary capabilities, expertise, and intellectual property, fostering innovation and market expansion. Furthermore, vendors are continuously optimizing existing products through lifecycle management strategies, such as developing new formulations, expanding indications, or pursuing combination therapies, to extend product life cycles and sustain revenue growth. Additionally, capital investments and government support are essential for the development and launch of advanced or upgraded devices. By executing these strategies, companies in the cancer immunotherapy market aim to drive innovation, expand market share, and ultimately improve patient outcomes, thereby fueling the growth of the global market during the forecast period.
Get more information on Cancer Immunotherapy Market by requesting a sample report
The market is segmented based on
According to Technavio, There are several factors that are causing the market to flourish during the forecast period, which are as follows:
However, the market also witnesses some limitations, which are as follows:
Rich Experience: 20+ years leading global market research, trusted insights across industries.
Unlock Business Potential with Technavio: Maximize ROI with Technavio's tailored market research: deep dives and actionable insights.
Your Guide to Market Success: Empower your business with Technavio's market research and future-proof your decisions.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
180 |
|
Base year |
2023 |
|
Historic period |
2018-2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 8.1% |
|
Market growth 2024-2028 |
USD 45.5 billion |
|
Market structure |
fragmentation |
|
YoY growth 2023-2024(%) |
7.32 |
|
Key countries |
US, Germany, China, France, and Canada |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Find out which segment is leading the market by accessing the free PDF report
The Cancer Immunotherapy Market has witnessed significant growth in recent years due to the development of innovative treatments for various types of cancer. Multiple myeloma patients have benefited from advancements such as Blinatumomab and Keytruda, which are used in combination with traditional therapy. CAR-T cell therapy, a type of immunotherapy, has shown promising results in the treatment of acute myeloid leukemia and other cancers. Companies like Immatics are working on developing new therapies, such as FLT3-targeting agents like quizartinib, to enhance the immune response against cancer cells. Hospital Pharmacies play a crucial role in the administration of these advanced therapies, including mAbs, checkpoint inhibitors, and cancer vaccines. Biosimilars of these drugs are also entering the market, providing cost-effective alternatives. Immunomodulators and targeted therapies continue to be key players in the market, with prostate, head & neck, breast, melanoma, colorectal, and lungs cancer being major indications. The future of cancer treatment lies in the combination of traditional and immunotherapies to maximize therapeutic efficacy.
The global pharmaceuticals market, encompassing entities involved in the research and development (R&D) or production of various drug categories including generics, non-generics, and veterinary drugs, is a significant segment of the larger healthcare industry. According to Technavio, the healthcare market size is determined by the consolidated revenue generated by providers of medical equipment, supplies, pharmaceuticals, biotechnology, and life sciences tools and services. Factors propelling the expansion of the pharmaceuticals market include the increasing global population aging, with the proportion of individuals above 60 years projected to reach nearly one-quarter in the US by 2050 and Europe by 2030. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
Safe and Secure SSL Encrypted
One user only.
Quick & easy download option
Unlimited user access (Within your organization).
Complimentary Customization Included
*For Enterprise license, go to checkout page
Get the report (PDF) sent to your email within minutes.
